Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?-Reference-Cited by-同舟云学术

Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?

Published:2019-12-06 Issue:23 Volume:3 Page:4021-4033
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Goldmann Luise¹,Duan Rundan¹,Kragh Thorsten²,Wittmann Georg²,Weber Christian¹³⁴^ORCID,Lorenz Reinhard¹,von Hundelshausen Philipp¹³^ORCID,Spannagl Michael²,Siess Wolfgang¹³

Affiliation:

1. Institute for Prevention of Cardiovascular Diseases and

2. Department of Transfusion Medicine, Cell Therapeutics and Hemostaseology, Ludwig-Maximilians University, Munich, Germany;

3. German Centre for Cardiovascular Research, partner site Munich Heart Alliance, Munich, Germany; and

4. Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands

Abstract

Key Points Six different BTKi’s blocked platelet activation in blood after FcγRIIA stimulation by cross-linking, anti-CD9 antibodies, or HIT serum. Established oral irreversible and novel reversible BTKi’s may offer a new option to treat HIT.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/23/4021/1547061/advancesadv2019000617.pdf

Reference62 articles.

1. CLINICAL PRACTICE. Heparin-induced thrombocytopenia;Greinacher;N Engl J Med,2015

2. The platelet Fc receptor, FcγRIIa;Qiao;Immunol Rev,2015

3. Human platelet IgG Fc receptor FcγRIIA in immunity and thrombosis;Arman;J Thromb Haemost,2015

4. Heparin-induced thrombocytopenia;Arepally;Blood,2017

5. Impact of the PI3-kinase/Akt pathway on ITAM and hemITAM receptors: haemostasis, platelet activation and antithrombotic therapy;Moroi;Biochem Pharmacol,2015

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive Characterization of BTK Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Non-covalent Mechanistic Signatures;2024-09-08

2. Platelet FcγRIIA: An emerging regulator and biomarker in cardiovascular disease and cancer;Thrombosis Research;2024-06

3. Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents;Cancers;2024-05-24

4. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases;Autoimmunity Reviews;2024-05

5. Heterogeneity and interplay: the multifaceted role of cancer-associated fibroblasts in the tumor and therapeutic strategies;Clinical and Translational Oncology;2024-04-11